Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Crit Rev Eukaryot Gene Expr ; 28(4): 321-327, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-30311580

RESUMEN

Alzheimer's disease (AD) is a major dementia disease worldwide with an increasing incidence rate among the elderly. It is a neurodegenerative disease with symptoms starting slowly and then progressing over time. There has been extensive research on AD prevention and treatment; however, there is no cure as of yet. Several drugs are being researched for the treatment and prevention of AD, with a rising interest in specific dietary compounds as potential interventions with lower side effects. One such dietary compound being tested is phytoestrogen. Phytoestrogens are chemically, structurally, and functionally similar to estrogen, which has numerous functions as a cognition-promoting agent; although, as a supplement it can be damaging. Phytoestrogens have the unique ability to substitute for estrogen in elderly individuals with Alzheimer's disease and depleted estrogen levels. This paper aims to contribute to the collective understanding of phytoestrogen's role in the treatment and prevention of Alzheimer's disease by describing its various mechanisms, including its ability to decrease amyloid beta peptide production, promote calcium outflow and acetylcholine release, and reduce Tau protein phosphorylation. The paper also addresses phytoestrogen's role as an anti-inflammatory and antioxidant agent for the cholinergic neurons associated with Alzheimer's disease.


Asunto(s)
Enfermedad de Alzheimer/tratamiento farmacológico , Enfermedad de Alzheimer/prevención & control , Fitoestrógenos/farmacología , Acetilcolina/metabolismo , Enfermedad de Alzheimer/metabolismo , Péptidos beta-Amiloides/metabolismo , Antioxidantes/metabolismo , Calcio/metabolismo , Humanos , Neuronas/efectos de los fármacos , Fosforilación/efectos de los fármacos , Fitoestrógenos/uso terapéutico , Proteínas tau/metabolismo
2.
Crit Rev Eukaryot Gene Expr ; 28(1): 67-72, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-29773015

RESUMEN

Over the past few decades, caffeine has been well recognized as a stimulant whose effects can be detected particularly in the central nervous system. A stimulating effect of caffeine has been found useful in treating patients with many neurological disorders, including Alzheimer's disease (AD). AD is reported to be a rapidly increasing public health problem with lack of a remedial treatment. However, the assumed protective effects of caffeine against AD are of huge interest. This study substantiates caffeine's role as a potential prevention agent against AD through several epidemiological studies. More than 75% of available study reports support the opinion that caffeine has a favorable effect against cognitive decline and AD. Moreover, other studies have discussed the effect of caffeine drinking and concluded several positive effects on cognitive functioning. The present study, however, focuses more on the potential mechanisms by which caffeine diminishes effects as well as delays the onset of AD.


Asunto(s)
Enfermedad de Alzheimer , Cafeína/uso terapéutico , Disfunción Cognitiva , Enfermedad de Alzheimer/complicaciones , Enfermedad de Alzheimer/tratamiento farmacológico , Estimulantes del Sistema Nervioso Central/uso terapéutico , Disfunción Cognitiva/tratamiento farmacológico , Disfunción Cognitiva/etiología , Humanos , Sustancias Protectoras/uso terapéutico
3.
Crit Rev Eukaryot Gene Expr ; 28(1): 87-92, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-29773017

RESUMEN

Considered as a chronic illness, gastroesophageal reflux disease (GERD) has manifested itself as a widespread condition throughout the adult population. As a growing epidemic, GERD has reached a staggering prevalence of 10% to 20% in the Western world, by affecting up to 30 million people in the United States alone. Sixty percent of individuals in an adult population will experience symptoms and the impact of GERD over a period of 12 months, whereas a remarkable 20% to 30% of individuals will have weekly symptoms. This rapid increase in the prevalence of the disease requires equally rapid management techniques. Although the disease itself has no cure, management of symptoms and certain pharmacological and surgical advancements have allowed for individuals affected by GERD to receive specific treatment options sufficient for them to live a healthy life. In this paper, such management options will be examined and discussed in reference to their effectiveness in treating the symptoms presented in GERD patients.


Asunto(s)
Reflujo Gastroesofágico/tratamiento farmacológico , Enfermedad Crónica/tratamiento farmacológico , Enfermedad Crónica/epidemiología , Reflujo Gastroesofágico/epidemiología , Humanos , Estados Unidos/epidemiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...